Northwire Canada EditionFriday, July 10, 2026
Northwire
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.58 +8.6% TUNG 1.72 +1.8% LGO 1.03 −1.0% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.31 −1.9% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.93 −0.6%
Other

Doseology Sciences rolls out Feed That Brain product

MOOD · Price

Executive Summary

  • Doseology Sciences Inc. has launched "Feed That Brain," a nicotine-free, caffeine-based oral stimulant pouch, initiating its first direct-to-consumer pilot program in the United States.
  • The product is available exclusively via the company's website and Amazon.com, aiming to validate oral pouch delivery as a scalable stimulant platform and evaluate consumer adoption among underserved demographics.
  • The company also announced the granting of restricted and performance share units to a director, aligning compensation with long-term value creation.

Key Details

  • Product Launch: Introduction of "Feed That Brain" energy pouches, a nicotine-free, caffeine-based oral stimulant designed for portion-controlled stimulation without sugar, smoke, or liquid consumption.
  • Distribution Channels: Available exclusively to U.S. consumers on the Feed That Brain website and Amazon.com.
  • Strategic Objective: The U.S. pilot serves to validate oral pouch delivery as a scalable platform, focusing on measuring consumer adoption, usage frequency, and repeat-purchase behavior.
  • Target Market: Focus on underserved demographics seeking alternatives to traditional energy drinks and portable, discreet delivery systems.
  • Executive Quote: Larry Latowsky, Executive Chairman, described the pilot as a "disciplined and deliberate step" to build a scalable oral stimulant platform and generate operational insights for responsible growth.
  • Equity Grant: Granted 140,000 restricted share units (RSUs) and 210,000 performance share units (PSUs) to a company director.
    • RSU Vesting: Equal monthly increments over 36 months from the date of grant.
    • PSU Vesting: Upon achievement of defined performance milestones.

Notable Quotes

  • "This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, executive chairman of Doseology. "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."
Read the original news release →

More from Doseology Sciences Inc